Plasma globotriaosylsphingosine as a biomarker of Fabry disease

Molecular Genetics and Metabolism

Volumn 100, Issue 3, 2010, Pages 257-261

  Togawa, Tadayasu ^a   Kodama, Takashi ^a   Suzuki, Toshihiro ^a   Sugawara, Kanako ^a   Tsukimura, Takahiro ^a   Ohashi, Toya ^b   Ishige, Nobuyuki ^c   Suzuki, Ken ^c   Kitagawa, Teruo ^c   Sakuraba, Hitoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tokyo Association of Health Service   (Japan)

Author keywords

Galactosidase A; Biomarker; Enzyme replacement therapy; Fabry disease; Globotriaosylceramide; Globotriaosylsphingosine

Indexed keywords

ALPHA GALACTOSIDASE; BIOLOGICAL MARKER; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEMIZYGOSITY; HETEROZYGOSITY; HUMAN; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FABRY DISEASE; FEMALE; GLYCOLIPIDS; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SPHINGOLIPIDS; TRIHEXOSYLCERAMIDES; YOUNG ADULT;

EID: 77953021876     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.03.020     Document Type: Article

References (27)

1. R.J. Desnick, Y.A. Ioannou, C.M. Eng, α-Galactosidase A deficiency: Fabry disease, in: C.R. Scriver, W.A. Sly, A.L. Beaudet, D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, eighth ed., McGraw-Hill Inc., New York, 2001, pp. 3733-3774.
2. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. 38 (2001) 769-775
3. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., and Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease. Am. J. Hum. Genet. 68 (2001) 711-722
4. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345 (2001) 9-16
5. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., Anderson T., Gillespie F., Oliver K.L., Jeffries N.O., Doo E., Liang T.J., Kreps C., Gunter K., Frei K., Crutchfield K., Selden R.F., and Brady R.O. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 97 (2000) 365-370
6. Weidemann F., Niemann M., Breunig F., Herrmann S., Beer M., Störk S., Voelker W., Ertl G., Wanner C., and Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119 (2009) 524-529
7. Schiffmann R., Ries M., Timmons M., Flaherty J.T., and Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 21 (2006) 345-354
8. Kitagawa T., Ishige N., Suzuki K., Owada M., Ohashi T., Kobayashi M., Eto Y., Tanaka A., Mills K., Winchester B., and Keutzer J. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol. Genet. Metab. 85 (2005) 196-202
9. Whitfield P.D., Calvin J., Hogg S., O'Driscoll E., Halsall D., Burling K., Maguire G., Wright N., Cox T.M., Meikle P.J., and Deegan P.B. Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 28 (2005) 21-33
10. Kitagawa T., Suzuki K., Ishige N., Ohashi T., Kobayashi M., Eto Y., Tanaka A., Odaka H., and Owada M. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr. Nephrol. 23 (2008) 1461-1471
11. Rozenfeld P.A., De Francesco N.P., Borrajo G.J., Ceci R., and Fossati C.A. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Clin. Chim. Acta 403 (2009) 194-197
12. Young E., Mills K., Morris P., Vellodi A., Lee P., Waldek S., and Winchester B. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Pediatr. 94 (2005) 51-54
13. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopmann W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., and Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA 105 (2008) 2812-2817
14. Sugawara K., Tajima Y., Kawashima I., Tsukimura T., Saito S., Ohno K., Iwamoto K., Kobayashi T., Itoh K., and Sakuraba H. Molecular interaction of imino sugars with human α-galactosidase: insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol. Genet. Metab. 96 (2009) 233-238
15. W.L. Hwu, Y.H. Chien, N.C. Lee, S.C. Chiang, R. Dobrovolny, A.C. Huang, H.Y. Yeh, M.C. Chao, S.J. Lin, T. Kitagawa, R.J. Desnick, L.W. Hsu, Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A), Hum. Mutat., doi: 10.1002/humu. 21074.
16. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., and Desnick R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79 (2006) 31-40
17. Rolfs A., Böttcher T., Zshiesche M., Morris P., Winchester B., Bauer P., Walter U., Mix E., Löhr M., Halzer K., Strauss U., Pahnke J., Grossmann A., and Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366 (2005) 1794-1796
18. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara A., Yoshida A., Kuriyama M., Hayashiba H., Sakuraba H., and Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N. Engl. J. Med. 333 (1995) 288-293
19. Bekri S., Enica A., Ghafari T., Plaza G., Champenois I., Choukroun G., Unwin R., and Jaeger P. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron 101 (2005) c33-c38
20. Groener J.E.M., Poorthuis B.J.H.M., Kuiper S., Helmond M.T.J., Hollak C.E.M., and Aerts J.M.F.G. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin. Chem. 53 (2007) 742-747
21. Mills K., Johnson A., and Winchester B. Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett. 515 (2002) 171-176
22. Suzuki K. Twenty-five years of the "psychosine hypothesis": a personal perspective of its history and present status. Neurochem. Res. 23 (1988) 251-259
23. Nilsson O., and Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J. Neurochem. 39 (1982) 709-718
24. Nilsson O., Månsson J.-E., Håkansson G., and Svennerholm L. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease. Biochim. Biophys. Acta 712 (1982) 453-463
25. Vanier M., and Svennerholm L. Chemical pathology of Krabbe disease: the occurrence of psychosine and other neutral sphingolipids. Adv. Exp. Med. Biol. 68 (1976) 115-126
26. Cleland W.W., and Kennedy E.P. The enzymatic synthesis of psychosine. J. Biol. Chem. 235 (1960) 45-51
27. Kobayashi T., Goto I., Okada S., Orii T., Ohno K., and Nakano T. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses. J. Neurochem. 59 (1992) 1452-1458